Real-World Experience With Maribavir for Treatment of Refractory or Resistant Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients and Hematologic Malignancy Patients.

Background: Refractory and/or resistant (R/R) cytomegalovirus (CMV) infection is a serious complication after allogeneic hematopoietic cell transplantation (HCT). Maribavir, an oral antiviral agent, was approved in November 2021 for the treatment of R/R CMV in transplant recipients. However, real-world data on the use of maribavir in HCT recipients and hematologic malignancy (HM) patients are limited.

Rare occurrence of triple primary malignant tumors: Dermatofibrosarcoma protuberans, lung adenocarcinoma and papillary thyroid carcinoma in a patient with genetic evaluation.

Triple primary malignancies are rare, involving the occurrence of three distinct, unrelated cancers in a single patient, requiring a personalized, multidisciplinary treatment approach. A 69-year-old male was diagnosed with dermatofibrosarcoma protuberans (DFSP), lung adenocarcinoma, and papillary thyroid carcinoma. After amputation for DFSP, following staging and genetic evaluation, a multidisciplinary tumor board designed a tailored treatment plan, adjuvant chemotherapy for lung adenocarcinoma while monitor regularly the thyroid carcinoma via ultrasound.

Effectiveness of the enhanced recovery after surgery (ERAS) program after lobectomy for lung cancer: a single-center observational study using propensity score matching in Vietnam.

Background: Postoperative complications and extended length of stays (LOS) following lobectomy for non-small cell lung cancer (NSCLC) remain significant healthcare and economic burdens, especially in developing countries with limited resources. This study evaluated the effectiveness of enhanced recovery after surgery (ERAS) protocols in addressing these issues.

Methods: This observational study compared two groups of patients, utilizing a prospective arm for ERAS and a retrospective arm for routine care.

HLA Compatibility and Graft Survival Rates Among Related and Unrelated Donors in Renal Transplantation.

Human leukocyte antigen (HLA) compatibility between donors and recipients plays a critical role in graft survival in renal transplantation. This study evaluates the impact of HLA mismatching on graft survival and rejection among renal transplant recipients with related and unrelated donors, considering factors such as age, sex, ABO blood type, and anti-HLA antibodies. We investigated the graft survival rates between related and unrelated donors in a prospective cohort study conducted from 2018 to 2020 at Cho Ray Hospital and People's Hospital 115 in Vietnam, involving 126 related and 82 unrelated donor-recipient pairs.